Cargando…
Use of cell proliferation data in cancer risk assessment: FDA view.
The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular...
Autor principal: | Scheuplein, R J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1519445/ https://www.ncbi.nlm.nih.gov/pubmed/8013401 |
Ejemplares similares
-
FDA eyes pharmacogenomics data.
por: Wakefield, Julie
Publicado: (2004) -
The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006) -
OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
por: Kass-Hout, Taha A, et al.
Publicado: (2016) -
FDA Risk Assessment of Seafood Contamination after the BP Oil Spill
por: Dickey, Robert W.
Publicado: (2012) -
Bringing FAIRness to FDA data through visualization
por: Espinoza Salomon, Juan
Publicado: (2023)